BioSpace News Archive

Qilu Pharmaceutical and Active Pharmaceutical Ingredients, announced that the results of the phase II study evaluating QL1706 plus chemotherapy +/- bevacizumab for the treatment of non-small cell lung cancer were released on 2 December 2022 in poster presentations at the European Society for Medical Oncology Asia Congress 2022.

Bionomics Limited today announced it will present data on the development of an oral tablet formulation of BNC210 for the treatment of Social Anxiety Disorder (SAD) and data on the pharmacometrics analysis and drug reformulation of BNC210 for the treatment of PTSD at the 61st Annual meeting of the American College of Neuropsychopharmacology (ACNP) to be held in-person Sunday through Wednesday, December 4-7, 2022 in Phoenix, Arizona.

Bio-Thera Solutions, a commercial-stage biopharmaceutical company developing a pipeline of innovative therapies and a pipeline of biosimilars, announced the company will present two posters at the 2022 San Antonio Breast Cancer Symposium taking place December 6 - 10, 2022 in San Antonio, Texas.

Focus-X Therapeutics, a nuclide drug company that was invested in and incubated by Viva Biotech, successfully reached an acquisition agreement with Full-Life Technologies Co., Ltd.

PainTEQ, a fast-growing medical innovation company and the creator of LinQ, a minimally invasive therapy for SI joint (SIJ) dysfunction, announced the appointment of Michael Mydra as its new Senior Vice President.

Ginkgo Bioworks Holdings, Inc. today announced that in connection with its transaction with Bayer CropScience LP (“Bayer”) on October 17, 2022, Ginkgo granted 9,868,143 restricted stock units to 139 new employees, and in connection with its acquisition of Zymergen Inc. (“Zymergen”) on October 19, 2022.

Vanda Pharmaceuticals Inc. (Vanda) (Nasdaq: VNDA) today reported results in a Phase II clinical study of VQW-765, a novel small molecule alpha 7 nicotinic acetylcholine receptor (α7-nAChR) partial agonist, in the treatment of acute performance anxiety in social situations, such as public speaking.

Adicet Bio, Inc. today announced that the Company will host a webcast presentation on Sunday, December 11, 2022 at 9:00 a.m. EST to discuss the most recent data-cut from its ongoing Phase 1 study evaluating the safety and tolerability of ADI-001 for the potential treatment of relapsed or refractory B-cell NHL.

Immunocore Holdings plc (Nasdaq: IMCR), and Gadeta B.V., announced today that they will collaborate on the first γδ ImmTAC® for solid tumors, including colorectal cancer.

BetterLife Pharma Inc. (“BetterLife” or the “Company”) (CSE: BETR / OTCQB: BETRF / FRA: NPAU) today announced that one of its scientific collaborators, Dr. Argel Aguilar-Valles from Carleton University’s Department of Neuroscience (Ottawa, Canada), will present on the anti-depressant activity of 2-bromo-LSD (“BETR-001”), the Company’s lead compound, at the upcoming ACNP Conference being held December 4 to 7 at Phoenix, Arizona, USA.